Medicare should only cover Biogen‘s Aduhelm drug for certain recipients who are enrolled in qualifying clinical trials, officials at the organization that oversees the national health insurance program proposed Tuesday evening. Biogen stock was tumbling.
If approved, the decision would restrict access to the first Alzheimer’s therapy approved in decades by the Food and Drug Administration.
Dr….